Dwight Evans is not making headlines this week. Zero Google News stories in the last 24 hours. But on Bluesky, at least one account noticed his name on an Intel sale filing and flagged it for the congressional-trading-watchers crowd. That's a thin news hook, so let's give them something real to work with: Evans has filed 5 disclosed stock trades in the last 90 days, is 0 for 8 on 30-day alpha across his full scored sample, and sold shares in a healthcare giant that sits squarely inside his committee jurisdiction. The public record is right there.
The Trading Record, Unvarnished
Per Evans's full disclosure record on Blind Trust, he's filed five sales since late March. The full scored sample covers 8 trades and shows 0 positive alpha outcomes against the S&P 500. Eight scored. Zero winners. Mean 30-day alpha: negative 5.7 percent.
The worst of it: he sold Micron Technology on March 24, a position in the 5K–$50K range, at negative 14.1 percent alpha over the following 30 days. He sold Quanta Services and Thermo Fisher Scientific on May 7, both in the K–5K range, at negative 7.7 and negative 7.8 percent alpha respectively. He sold Intel on the same day for negative 1.5 percent. He sold American Tower on May 11 and basically broke even at negative 0.0 percent — technically his best trade in the sample.
Eight scored trades. Zero wins. The best outcome rounded to zero.
To be clear about what this scoring means: 30-day alpha is excess return versus the S&P 500 after the trade date. This is the full sample, not a cherry-picked window. Evans's disclosed portfolio moves, as a group, have underperformed the index on every single scored trade. Selling stocks at the wrong time is bipartisan.
The One Trade That Raises a Different Question
Evans sits on the House Committee on Ways and Means, specifically the Health and Work and Welfare subcommittees. Ways and Means Health has jurisdiction over Medicare, Medicaid, and the broader healthcare financing architecture that shapes the regulatory environment for large life sciences companies.
On May 7, Evans sold shares of Thermo Fisher Scientific (ticker: TMO), a life sciences and laboratory instruments company with significant exposure to that regulatory environment. The amount: K–5K. The 30-day alpha: negative 7.8 percent.
Blind Trust flags this as a committee overlap trade. Evans is not just a member who happened to sell a healthcare-adjacent stock on a random Tuesday. He's a member with direct committee jurisdiction over healthcare policy who sold a healthcare-sector holding. The disclosure is in the public record. The committee assignment is in the public record. There are no vote-trade overlaps flagged in the data for this specific sale — the timing of the May 7 trade doesn't line up with a specific floor vote the data marks as notable. The overlap is structural: committee remit plus sector holding.
The May 7 Sell-Off
Three of Evans's five 90-day trades landed on a single day. May 7: Intel (INTC), Quanta Services (PWR), and Thermo Fisher Scientific (TMO), all sales, all in the K–5K range. A concentrated offload across three different sectors in one session.
Intel is a semiconductor company navigating tariff exposure and a multi-year turnaround story. Quanta Services is an electrical infrastructure contractor with significant exposure to energy-transition and grid-buildout spending. Thermo Fisher is life sciences equipment and services. The three don't obviously rhyme as a portfolio thesis. They rhyme as a liquidation.
What triggered a three-ticker exit on May 7? The disclosure doesn't say. Disclosures never say. Members are required to report the trade. They are not required to explain it, justify it, or recuse from related votes.
The Floor Votes: What They Are and What They Are Not
Evans voted Yea on May 20 on a cluster of banking-adjacent legislation: the American Access to Banking Act (H.R. 4544), the Community Bank Deposit Access Act of 2025 (H.R. 5317), and the Keeping Deposits Local Act (H.R. 3234), all of which passed.
Evans is on Ways and Means, not Financial Services. Bank deposit legislation sits in Financial Services' jurisdiction. Floor votes on bills outside a member's committee are not a conflict-of-interest angle — every member votes on the floor on bills their committee never touched. These votes tell us Evans showed up and voted with a majority on banking-access legislation. They don't tell us more than that.
He also voted Nay on the Veterans 2nd Amendment Protection Act (H.R. 1041) on May 21, which passed anyway, and Nay on the Sharri Briley and Eric Edmundson Veterans Benefits Expansion Act, which also passed. On June 11, he voted Nay on extending FISA surveillance authorities under H.R. 9238, which failed. None of these connect to the trading record.
What Bluesky Actually Said
The social chatter that brought Evans's name up this week centered on the Intel sale. One Bluesky post flagged it as a congressional sale of INTC over the last 90 days, naming Evans specifically. Eight total social mentions in the data. The other posts were baseball-adjacent and irrelevant.
The Intel sale, taken alone, is the second-least-interesting trade Evans filed this quarter. Negative 1.5 percent alpha, no committee overlap, no vote proximity. A sub-5K sale of a struggling chipmaker by a back-bench member. The Thermo Fisher sale is more interesting. The 0-for-8 record is more interesting. The concentrated May 7 exit is more interesting.
Bluesky found the right thread and pulled the wrong end of it.
The Bigger Picture
Evans is a Democrat representing Pennsylvania's 3rd, a Philadelphia-anchored district. He's been in the House since 2016 and on Ways and Means for a significant portion of that tenure. Ways and Means is one of the more consequential committee assignments in the chamber, covering tax policy, trade, Social Security, Medicare, and Medicaid. The Health subcommittee processes legislation that can directly move large-cap pharmaceutical and life sciences stocks.
Across 8 scored trades, Evans has posted negative alpha on all 8. Mean: negative 5.7 percent versus the index. One of those 8 trades carries a committee overlap flag — the TMO sale, in healthcare, while sitting on the Ways and Means Health subcommittee. The alpha on that trade was negative 7.8 percent, so if there was any information advantage in play, it didn't show up in the price action. The timing is what it is. The committee seat is what it is. The receipts are public. Make of them what you make of them.